Erratum: Mcl-1 Inhibition: Managing Malignancy in Multiple Myeloma

Erratum: Mcl-1 Inhibition: Managing Malignancy in Multiple Myeloma

Bibliographic Details
Main Author:	Frontiers Production Office
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2021-08-01
Series:	Frontiers in Pharmacology
Subjects:	multiple myeloma drug resistant Mcl-1 Bcl-2 homology 3 mimetics apoptosis
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2021.758130/full

Similar Items

Mcl-1 Inhibition: Managing Malignancy in Multiple Myeloma
by: Omar S. Al-Odat, et al.
Published: (2021-07-01)

Selective Small Molecule Myeloid Cell Leukemia-1 (MCL-1) Inhibitors: Novel Agents in Cancer Therapy
by: Hoda Sobhy Ibrahim, et al.
Published: (2019-12-01)

AT101 [(-)-Gossypol] Selectively Inhibits MCL1 and Sensitizes Carcinoma to BH3 Mimetics by Inducing and Stabilizing NOXA
by: David J. Mallick, et al.
Published: (2020-08-01)

Restoring Apoptosis with BH3 Mimetics in Mature B-Cell Malignancies
by: Maxime Jullien, et al.
Published: (2020-03-01)

BH3 Mimetics for the Treatment of B-Cell Malignancies—Insights and Lessons from the Clinic
by: Victor S. Lin, et al.
Published: (2020-11-01)

Role and Regulation of Pro-survival BCL-2 Proteins in Multiple Myeloma
by: Anne Slomp, et al.
Published: (2018-11-01)

Dinaciclib synergizes with BH3 mimetics targeting BCL‐2 and BCL‐XL in multiple myeloma cell lines partially dependent on MCL‐1 and in plasma cells from patients
by: Manuel Beltrán‐Visiedo, et al.
Published: (2023-12-01)

Targeting MCL-1 protein to treat cancer: opportunities and challenges
by: Shady I. Tantawy, et al.
Published: (2023-07-01)

Targeting MCL-1 in cancer: current status and perspectives
by: Haolan Wang, et al.
Published: (2021-04-01)

AT-101 Enhances the Antitumor Activity of Lenalidomide in Patients with Multiple Myeloma
by: Sikander Ailawadhi, et al.
Published: (2023-01-01)

BOK-MCL1 transmembrane interactions: a challenging target for cancer therapy
by: Mónica Sancho, et al.
Published: (2021-01-01)

A novel Mcl-1 inhibitor synergizes with venetoclax to induce apoptosis in cancer cells
by: Tianming Zhao, et al.
Published: (2023-01-01)

Bak and Bcl-xL Participate in Regulating Sensitivity of Solid Tumor Derived Cell Lines to Mcl-1 Inhibitors
by: Viacheslav V. Senichkin, et al.
Published: (2021-12-01)

Upregulation of Mcl-1S Causes Cell-Cycle Perturbations and DNA Damage Accumulation
by: Alena Y. Streletskaia, et al.
Published: (2020-09-01)

Regulation of neuronal autophagy and cell survival by MCL1 in Alzheimer’s disease
by: Abdol-Hossein Rezaeian, et al.
Published: (2022-01-01)

Marine Polyether Phycotoxin Palytoxin Induces Apoptotic Cell Death via Mcl-1 and Bcl-2 Downregulation
by: Jaemyun Kim, et al.
Published: (2023-04-01)

Enhanced Apoptosis and Loss of Cell Viability in Melanoma Cells by Combined Inhibition of ERK and Mcl-1 Is Related to Loss of Mitochondrial Membrane Potential, Caspase Activation and Upregulation of Proapoptotic Bcl-2 Proteins
by: Zhe Peng, et al.
Published: (2023-03-01)

Erratum: The Emerging Role of Extracellular Vesicle-Associated RNAs in the Multiple Myeloma Microenvironment
by: Frontiers Production Office
Published: (2021-07-01)

Potential mechanisms of resistance to venetoclax and strategies to circumvent it
by: Stephen K. Tahir, et al.
Published: (2017-06-01)

Physiological Functions of Mcl-1: Insights From Genetic Mouse Models
by: Hui San Chin, et al.
Published: (2021-07-01)

MCL1 Inhibition Overcomes the Aggressiveness Features of Triple-Negative Breast Cancer MDA-MB-231 Cells
by: Giovanni Pratelli, et al.
Published: (2023-07-01)

BCL-2 as therapeutic target for hematological malignancies
by: Guilherme Fleury Perini, et al.
Published: (2018-05-01)

Updates in the Use of BCL-2-Family Small Molecule Inhibitors for the Treatment of Relapsed/Refractory Multiple Myeloma
by: Ricardo D. Parrondo, et al.
Published: (2022-07-01)

Promising Anti-Mitochondrial Agents for Overcoming Acquired Drug Resistance in Multiple Myeloma
by: Vanessa Innao, et al.
Published: (2021-02-01)

Co-operation of MCL-1 and BCL-XL anti-apoptotic proteins in stromal protection of MM cells from carfilzomib mediated cytotoxicity
by: Daria Galas-Filipowicz, et al.
Published: (2024-04-01)

The downregulation of Mcl-1 via USP9X inhibition sensitizes solid tumors to Bcl-xl inhibition
by: Peddaboina Chander, et al.
Published: (2012-11-01)

Targeting Apoptotic Pathways in Acute Myeloid Leukaemia
by: Jonathan R. Sillar, et al.
Published: (2019-10-01)

BCL2 Family Inhibitors in the Biology and Treatment of Multiple Myeloma
by: Gupta VA, et al.
Published: (2021-03-01)

Chromothripsis in Treatment Resistance in Multiple Myeloma
by: Kyoung Joo Lee, et al.
Published: (2017-09-01)

Targeting Mcl-1 Degradation by Bergenin Inhibits Tumorigenesis of Colorectal Cancer Cells
by: Yu Gan, et al.
Published: (2023-02-01)

Combination strategies to overcome resistance to the BCL2 inhibitor venetoclax in hematologic malignancies
by: XiaoYan Yue, et al.
Published: (2020-10-01)

Different Types of Cell Cycle- and Apoptosis- Related Gene Expressions Alter in Corticosteroid-, Vincristine-, and Melphalan-Resistant U-266 Multiple Myeloma Cell Lines
by: Pelin Mutlu, et al.
Published: (2014-08-01)

Apoptotic machinery diversity in Multiple Myeloma molecular subtypes.
by: Patricia eGomez-Bougie, et al.
Published: (2013-12-01)

Effect of oxaliplatin on the survival rate of human Y79 cells after down-regulation of Mcl-1
by: Lu Zhou, et al.
Published: (2017-12-01)

Mcl-1 levels critically impact the sensitivities of human colorectal cancer cells to APG-1252-M1, a novel Bcl-2/Bcl-XL dual inhibitor that induces Bax-dependent apoptosis
by: Weilong Yao, et al.
Published: (2022-07-01)

BH3 Mimetic Sensitivity of Colorectal Cancer Cell Lines in Correlation with Molecular Features Identifies Predictors of Response
by: Le Zhang, et al.
Published: (2021-04-01)

Spontaneous apoptosis and BCL2 gene expression as predictors of early death and short overall survival in acute leukemia patients: a prospective, case cohort study
by: Huda F. Ebian, et al.
Published: (2021-11-01)

Bilirubin inhibits the anticancer activity of sorafenib by blocking MCL-1 degradation in hepatocellular carcinoma cells
by: Leyi Yao, et al.
Published: (2022-07-01)

BH3-mimetics: recent developments in cancer therapy
by: Paul A. Townsend, et al.
Published: (2021-11-01)

The prognostic impact of t(11;14) in multiple myeloma: A real‐world analysis from the Australian Lymphoma Leukaemia Group (ALLG) and the Australian Myeloma and Related Diseases Registry (MRDR)
by: Kenneth JC Lim, et al.
Published: (2023-08-01)